SCHEMBL2455485

SCHEMBL2455485

COc1cccc(Cc2nccc3cc(OC)c(OC)cc23)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 10/20 0.74
PDE3A Q14432 7/20 0.74
PDE3B Q13370 6/20 0.74
SMN1; SMN2 Q16637 5/20 0.71
CYP3A4 P08684 4/20 0.71
MAPK1 P28482 4/20 0.71
LMNA P02545 3/20 0.71
USP2 O75604 2/20 0.71
ALDH1A1 P00352 2/20 0.71
HIF1A Q16665 2/20 0.71
RAB9A P51151 2/20 0.71
CYP1A2 P05177 2/20 0.71
CYP2C9 P11712 2/20 0.71
TSHR P16473 2/20 0.71
PDE4A P27815 2/20 0.71
KCNH2 Q12809 2/20 0.71
PDE4D Q08499 2/20 0.71
PDE2A O00408 1/20 0.71
ABCC4 O15439 1/20 0.71
PDE5A O76074 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11845148 0.86 PDE10A (0.77) PDE10APDE3APDE3BSMN1; SMN2CYP3A4
Hydrochloric Acid SCHEMBL11816554 0.85 PDE10A (0.75) PDE10APDE3APDE3BSMN1; SMN2CYP3A4
SCHEMBL1445574 0.85 PDE10A (1.00) PDE10APDE3APDE3BSMN1; SMN2CYP3A4
SCHEMBL21690568 0.84 PDE10A (0.76) PDE10APDE3APDE3BSMN1; SMN2CYP3A4
SCHEMBL1445580 0.84 PDE10A (0.51) PDE10APDE3APDE3BSMN1; SMN2CYP3A4
Papaverine SCHEMBL29387160 0.83 PDE10A (1.00) PDE10APDE3APDE3BSMN1; SMN2CYP3A4
Papaverine SCHEMBL29360983 0.83 PDE10A (1.00) PDE10APDE3APDE3BSMN1; SMN2CYP3A4
Papaverine SCHEMBL34702 0.83 PDE10A (1.00) PDE10APDE3APDE3BSMN1; SMN2CYP3A4
Papaverine SCHEMBL9551009 0.83 PDE10A (1.00) PDE10APDE3APDE3BSMN1; SMN2CYP3A4
Papaverine SCHEMBL8691148 0.82 PDE10A (0.97) PDE10APDE3APDE3BSMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011146819-A2 METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES DMD THERAPIES, LLC (US) 2011-11-24 WO disclosed
US-20110224128-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY WHALEN ANNE 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224128-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY PYGM, TNNC1, MYOF PDE10A 159/4885PDE3A 49/4885PDE3B 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.